JNJ · Johnson & Johnson
Price
Snapshot
50 fields · last close| Market Cap | $615.9B |
| P/E | 38.26 |
| Float | 2.41B |
| Beta | 0.21 |
| Volatility | 5.1% |
| Exchange | NYSE |
| Sector | Pharmaceuticals |
| Cap tier | Mega cap |
| Macro sensitivity | Low |
| Clavix score | 80.3 |
| Price | 253.62 |
| Change | −0.76% |
| Prev Close | 255.56 |
| Open | 255.52 |
| Day Low | 254.00 |
| Day High | 257.55 |
| Avg Vol | 8 |
| Avg $ Vol | $2.07B |
| 52W High | 281.07 |
| 52W Low | 184.66 |
| 52W Pos | 71.5% |
| From High | −9.77% |
| From Low | +37.34% |
| Max DD 1Y | −10.96% |
| Spread | 0.10% |
| Liquidity | Deep |
| SMA 20 | −2.97% |
| SMA 50 | −4.38% |
| SMA 200 | +3.77% |
| RSI (14) | 43.7 |
| Vol 30D | 23.9% |
| Vol 90D | 25.1% |
| 1Y Range | 185–281 |
| Daily bars | 537 |
| Perf Week | −2.25% |
| Perf Month | −5.43% |
| Perf Quarter | +2.71% |
| Perf Half Y | +10.78% |
| Perf Year | +33.02% |
| Perf YTD | +22.31% |
| Prev Day | −0.76% |
| Clavix | A- |
| Debt / Eq | 0.49 |
| Curr Ratio | 1.03 |
| Int Cover | 35.2× |
| FCF Margin | 20.9% |
| Rev Growth | +6.0% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 5 / 14 |
What JNJ does
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.
This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand.
The company was founded in 1886 and is based in New Brunswick, New Jersey.
Clavix risk grade
regraded every trading dayJNJ grades A-, 80.3 of 100. Steadiest on Macro Resilience (68), most exposed on News Sentiment (44, fragile). 2 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 5 of 14 in Pharmaceuticals by Clavix score.
How rough the ride is
| JNJ | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 0.21 | 0.44 |
| Volatilityannualized | 5.1% | 10.9% |
| Max drawdown, past yearworst peak-to-trough fall | −11.0% | — |
| Typical daily movemedian absolute daily change | 0.79% | — |
| Days beyond ±3%of the last 252 sessions | 8 (3%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| JNJ | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 0.21 | 0.44 |
| Macro sensitivityrate, dollar and credit exposure bucket | Low | Low 67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| JNJ | |
|---|---|
| 1 week | −2.2% |
| 1 month | −5.4% |
| Year to date | +22.3% |
| 1 year | +33.0% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| JNJ | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 2 Oct |
| Average score0 most bearish, 100 most bullish | 58 |
| Bullish · bearisharticles above 60 · below 40 | 19 · 7 |
| Directionarticles whose tone is improving vs worsening | 19 ↑ 7 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| JNJ | |
|---|---|
| Revenue growthyear over year | +6.0% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openJohnson & Johnson announced one-year results from the Phase 3 FUZION study showing TREMFYA (guselkumab) maintained or improved combined fistula remission through 48 weeks in adults with Crohn's disease and perianal fistula, with the 100 mg dose group rising from 28% remission at Week 24 to 35% at Week 48. The company says TREMFYA is the only IL-23 inhibitor to deliver this level of durable fistula remission through 48 weeks.
The article is a brief notice repeating a single headline: law firm SBS Law is inviting Johnson & Johnson investors with at least $100,000 in losses to join a potential fraud investigation against JNJ. No additional details, allegations, or findings are provided in the article body.
The law firm SBS Law is inviting Johnson & Johnson investors who have lost at least $100,000 to join a fraud investigation it is conducting against the company. No details of the alleged fraud, any filing, or company response are provided in the article.
Johnson & Johnson raised its full-year sales forecast after strong third-quarter results, putting the company on track to surpass $100 billion in annual revenue for the first time, driven by its innovative medicine business even as its medical devices segment faces temporary global headwinds.
Johnson & Johnson raised its full-year sales outlook after Q3 2026 revenue grew 6% excluding currency effects. Its drug division grew 7.9% on cancer treatments and Tremfya, while its medical device unit grew just 2.5% due to Middle East disruptions, a Chinese government bulk-buying program, and slow uptake of Abiomed heart pumps.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| MRK | Merck & Co Inc | B+ | $360.1B | 113.48 | 0.12 | Compare |
| LLY | Eli Lilly and Co | B | $1.18T | 44.30 | 0.42 | Compare |
| AZN | AstraZeneca PLC | B+ | $196.9B | 25.12 | 1.27 | Compare |
| PFE | Pfizer Inc | A- | $168.6B | 38.91 | 0.31 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $122.1B | 13.15 | 0.19 | Compare |
| RPRX | Royalty Pharma PLC | A | $35.06B | 43.01 | 0.39 | Compare |
| ZTS | Zoetis Inc | B+ | $31.87B | 12.55 | 0.70 | Compare |
| VTRS | Viatris Inc | B+ | $21.43B | — | 0.89 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.